title: Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud's phenomenon) in a case of early systemic sclerosis.
authors.affiliation: Rehabilitation Institute of Montescano, Foundation S. Maugeri-Pavia, IRCCS, Italy.
authors.forename: Roberto
authors.initials: R
authors.lastname: Casale
authors.forename: Sergio
authors.initials: S
authors.lastname: Generini
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Luppi
authors.forename: Alberto
authors.initials: A
authors.lastname: Pignone
authors.forename: Marco
authors.initials: M
authors.lastname: Matucci-Cerinic
mesh_terms: D018501:Antirheumatic Agents / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011658:Pulmonary Fibrosis / Q000188:drug therapy* / Q000209:etiology; D020551:Pulse Therapy, Drug; D011928:Raynaud Disease / Q000188:drug therapy* / Q000209:etiology; D012595:Scleroderma, Systemic / Q000150:complications / Q000188:drug therapy*; D013564:Sympathetic Nervous System / Q000187:drug effects
chemical_list: D018501:Antirheumatic Agents; D003520:Cyclophosphamide